Brought to you by 
CytoTherapeutics sells cell technology to Neurotech SA
04 Jan 2022
Executive Summary
CytoTherapeutics, in exchange for a (uf)$3mm up-front payment and sales royalties, has sold Neurotech SA (start-up focusing on cell therapies for neurological and retinal disorders) its encapsulated cell technology (ECT). CytoTherapeutics will also receive revenues from third parties to which Neurotech outlicenses the technology, and retains nonexclusive rights to use ECT both in combination with its stem-cell technology and for developing vaccines for infectious diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CytoTherapeutics sells cell technology to Neurotech SA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice